Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 20/20 | 0.85 |
| ▸ | SLC5A1 | P13866 | 3/20 | 0.85 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.85 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.85 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.85 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15887584 | 1.00 | SLC5A2 (0.85) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 | |
| SCHEMBL10062752 | 1.00 | SLC5A2 (0.85) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 | |
| SCHEMBL147477 | 1.00 | SLC5A2 (0.85) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 | |
| SCHEMBL23135183 | 0.93 | SLC5A2 (0.84) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 | |
| SCHEMBL17294095 | 0.93 | SLC5A2 (0.83) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 | |
| SCHEMBL28404062 | 0.93 | SLC5A2 (0.83) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 | |
| Canagliflozin Anhydrous SCHEMBL16421559 | 0.92 | SLC5A2 (1.00) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 | |
| Canagliflozin Anhydrous SCHEMBL16075101 | 0.92 | SLC5A2 (1.00) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 | |
| Canagliflozin Anhydrous SCHEMBL19493514 | 0.92 | SLC5A2 (1.00) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 | |
| Canagliflozin Anhydrous SCHEMBL873848 | 0.92 | SLC5A2 (1.00) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9616028-B2 | Bilayer tablet formulations | ASTRAZENECA AB (SE) | 2017-04-11 | — | — | US | disclosed |
| US-20150238421-A1 | Bilayer Tablet Formulations | ASTRAZENECA AB (SE) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150238421-A1 | Bilayer Tablet Formulations | SLC5A2, SLC5A1, GLP1R | SLC5A2 1/4885SLC5A1 2/4885ABCB11 315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.